Effective dose and safety of remimazolam and propofol in gastroscopy for patients with liver cirrhosis

Status

Recruiting

Phases

Early Phase 1

Study type

Interventional

Source

ChiCTR

Registry ID

ChiCTR2200057794

Enrollment

Unknown

Registered

2022-03-17

Start date

2022-03-10

Completion date

Unknown

Last updated

2023-11-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

liver cirrhosis

Interventions

Propofol group:Propofol

Remimazolam group:Remimazolam

Eligibility

Sex/Gender

All

Age

20 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Patients with cirrhosis of the esophagus and gastric fundus varicose ligation, who want to undergo gastroscopy review; 2. Patients aged 20 to 80 years; 3. Agree to receive painless gastroscopy and sign informed consent.

Exclusion criteria

Exclusion criteria: 1. ASA grade IV or V; 2. Long-term use of analgesic or sedative drugs; 3. Hepatic encephalopathy; 4. Neurological diseases such as Alzheimer's or Parkinson's disease; 5. Allergic to benzodiazepines or opioids; 6. Refusing to sign informed consent.

Design outcomes

Primary

Measure	Time frame
Blood pressrue;Heart rate;Blood oxygen saturation;	—

Secondary

Measure	Time frame
Modified Observer's Assessment of Alertness/Sedation;Adverse reactions;The recovery time;	—

Countries

China

Contacts

Public ContactShi Fu

317449197@qq.com+86 18006353835

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026